Good luck with your interview, maybe you could post on here later and tell us how it went etc.
good luck
this looks like very powerful stuff:
http://www.hivandhepatitis.com/2008icr/aasld/docs/111108_c.html
" rapid decline in HCV viral load was observed in all patients, with maximal decline 2-4 days after starting BI201335.
• With the exception of 1 patient in the 20 mg group, all participants receiving BI201335 (96.2%) achieved > 2 log10 decline in HCV RNA during the monotherapy period."
http://hepatitiscnewdrugs.blogspot.com/2011/04/bi-201335-positive-phase-2-results.html
"BERLIN, Germany, and RIDGEFIELD, CT, April 1, 2011 – New data presented today at the 46th Annual Meeting of the European Association for the Study of the Liver (EASL) demonstrate the antiviral activity of Boehringer Ingelheim's once-daily oral protease inhibitor, BI 201335, in both treatment-naïve and -experienced patients with chronic genotype-1 (GT1) hepatitis C virus (HCV), the most challenging genotype of HCV to treat. Results from SILEN-C1 show a sustained viral response (SVR) in 71 to 83 percent of treatment-naïve patients who received BI 201335 once-daily plus the current standard-of-care (SOC) [pegylated interferon (PegIFN) and ribavirin (RBV)]."
• 100% of patients in the 48 mg, 120 mg, and 240 mg BI201335 dose groups achieved > 2.8 log10 drop in HCV viral load during the first few days of monotherapy."
Great information, sounds very promising. Now I'm getting excited...